Introduction
Obesity is becoming a major health issue in patients with COPD, as it is in the general population. Several studies have reported an increased proportion of patients with COPD who are either overweight or obese. [1] [2] [3] [4] Considering the well-established link between obesity and hypertension, type 2 diabetes, cancer and cardiovascular diseases (CVDs) 5 and the fact that COPD is an independent risk factor for CVDs, 6 this increased prevalence of obesity in COPD is a source of concern. Consistent with these observations, all-cause mortality and cardiovascular mortality are also increased in patients with COPD. 7 Depending on COPD severity, CVDs are the primary cause of mortality in 20%-27% of patients with COPD. 8, 9 One important issue to consider is that body mass index (BMI) is only a crude index of body composition while not allowing the quantification of ectopic fat accumulation. Rather than body size, body shape may be important to consider in the interpretation of the relationship between obesity and COPD. For instance, it is very well documented that the adverse metabolic and cardiovascular consequences of obesity are largely explained by the presence of unwanted adipose tissue (AT) accumulation in the abdomen and in normally lean tissues such as the liver, the heart and the skeletal muscles (collectively called ectopic fat tissue accumulation). 10 Individuals with a selective accumulation of ectopic fat are at increased risk of developing features of the metabolic syndrome, diabetes, an atherogenic dyslipidemia, or CVDs compared to those who preferentially accumulate lipids in subcutaneous "healthy" AT. 10 We took advantage of the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) cohort with a 3-year follow-up to address the following questions: 1) Is COPD associated with increased ectopic fat accumulation within the abdomen and in the muscles? 2) Does ectopic fat accumulation modify the expression of COPD in being associated with reduced functional and health status, as well as with forced expiratory volume in 1 second (FEV 1 ) rate of decline, exacerbations, mortality and cardiovascular comorbidities? Our overarching hypothesis was that COPD would be associated with increased ectopic fat accumulation compared to controls with normal lung function and that this would be associated with adverse clinical outcomes.
Methods study design and patients ECLIPSE (ClinicalTrials.gov, NCT00292552) was a multicenter, observational and longitudinal study to identify surrogate markers of COPD progression. 11 It enrolled 2,164 current or ex-smokers ($10 pack-years) with Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages 2-4, 337 smokers with normal lung function and 245 neversmokers. 12 All ECLIPSE participants underwent a low-dose volumetric computed tomography (CT) scan of the chest at baseline. In a subset of them that constitutes the population for the current report, a valid CT scan slice at L2-L3 could be identified, allowing to assess body composition from which fat and muscle densities, a reflection of tissue fatty infiltration, could be accurately quantified. 13 Patients' characteristics (age, race, sex, smoking history), chest CT scan, pulmonary function tests, St Georges' Respiratory Questionnaire (SGRQ) score and 6-minute walking distance (6MWD) were obtained at baseline and yearly for the 3-year study duration as previously reported. 11, 14, 15 Standardized questionnaires were used to record comorbidity at baseline. COPD exacerbations and mortality were also recorded. All patients provided written informed consent, and the study was approved by the ethics committees of the participating centers. The ECLIPSE steering and scientific committees approved the protocol for this substudy (Table S1 ).
Body composition and coronary artery calcification assessment
All ECLIPSE participants underwent a low-dose volumetric CT scan of the chest at baseline with the following protocol: 120-kV peak, 40 mA, and 1.00-or 1.25-mm slice thickness, at full inspiration. For the purpose of this ECLIPSE substudy, we analyzed all subjects with a thoracic CT scan that contained images at L2-L3 intervertebral space. Ectopic fat accumulation was quantified by measuring cross-sectional area (CSA) of visceral adipose tissue (VAT) and muscle tissue (MT) attenuation, a reflection of muscle fat infiltration. Subcutaneous adipose tissue (SCAT) and CSAs of MT were also assessed. Measures of fat and MT (psoas, paraspinal and abdominal wall muscles) CSA and attenuation were performed by the same investigator (MM) using the body composition analysis platform of the Institut universitaire de cardiologie et de pneumologie de Québec and a specialized image analysis software (sliceOmatic; TomoVision, Montreal, QC, Canada) according to standardized techniques ( Figure 1) . 13 CSAs of AT and MT were measured using an attenuation range of −190 to −30 Hounsfield units (HUs) and −29 to 130 HUs, respectively. The mean attenuation value in HU of each structure was generated. To avoid subjectivity in the separation between SCAT and VAT, these two fat tissues were separated from each other midway in the thickness of abdominal wall muscles. Subjects for whom a tissue surface area .1 cm 2 fell outside the field of view of the scope were excluded from further analysis. A random selection of 10% of all segmented images was redone by the same evaluator to assess for intraobserver variation. Interobserver variation was evaluated on a random sample of 10% of the segmented images that were also analyzed by a second imaging expert. We also took advantage of the thoracic CT scan to quantify coronary artery calcification, a surrogate of coronary artery disease, using standardized techniques. 16 
statistical analyses
Characteristics were compared between patients with COPD and controls (smokers with normal lung function and never-smokers), using Student's t-test statistics for 17 The overall test-retest reproducibility of each body composition parameter was assessed by calculating a Pearson's correlation coefficient between evaluation 1 and evaluation 2 for each CT body composition parameter. Test-retest reliability was evaluated using intraclass correlation coefficient (ICC) as it reflects both systematic and random differences in test measures. 18 An ICC .0.75 was judged to be excellent. 19 CT body composition variables were compared between patients with COPD and controls, and also across GOLD spirometric grades, using a multivariate analysis of covariance (MANCOVA) model, with age, sex, BMI and smoking status included as covariates. When a significant effect of groups or subgroups were identified, univariate analysis of covariance (ANCOVA) models were adjusted to investigate which body composition variables were different, and least significant difference-protected multiple comparisons were performed to differentiate the subgroups. The association between body composition parameters with clinical outcomes of interest (6MWD, exacerbation rate, quality of life, FEV 1 decline) was addressed using the Cochran-Armitage trend test to determine a dose-response relationship between CSA of VAT, mean MT attenuation, CSA of MT and each of the clinical outcomes. For this analysis, body composition parameters (explanatory variables) were expressed in four equal groups determined by their quartiles. In this analysis, quartile 1 was considered as the reference value, while quartiles 2, 3 and 4 indicated progressive increase in ectopic fat accumulation or decrease in CSA of MT. Each patient-reported outcome was expressed as dichotomous variables using specific cut-points: 350 m for the 6MWD, 20 more than or equal to 
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Martin et al two exacerbations per year, 17 SGRQ score .25 17 and FEV 1 decline .40 mL/year. 21 The impact of body composition on comorbidities was assessed by logistic regression models, while its relationship with survival was studied using a Cox proportional hazards regression model. All analyses were controlled for age, sex, BMI, smoking status and FEV 1 . P-values ,0.05 were considered statistically significant. Data analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
We identified 585 patients (511 patients with COPD and 74 controls) for whom a CT slice at L2-L3 could be analyzed for body composition assessment. Patients' characteristics are outlined in Table 1 . Patients with COPD and controls had similar BMI but important differences were otherwise noted: patients with COPD were older, had a higher proportion of men and were current/former smokers compared to controls. They also exhibited higher SGRQ scores (worse healthrelated quality of life), greater prevalence of cardiovascular comorbidities (angina, heart attack, myocardial infarction, stroke and heart failure), hypertension and greater coronary artery calcification score than controls. During the 3-year follow-up, 50 deaths were recorded (49 patients with COPD and one control), resulting in lower mean survival days in patients with COPD. A total of 1,661 moderate-to-severe exacerbations were reported in patients with COPD, with a mean exacerbation rate of 1.28±0.06/year/patient (range: 0-9/year/patient).
The Pearson's coefficient and ICC for each body composition parameter are reported in Table 2 and show an excellent intra-and inter-observer reproducibility of our body composition measurements.
CT body composition data adjusted for age, sex, smoker status and BMI are presented in Figure 2 . For a similar BMI (Figure 2A ), patients with COPD exhibited higher CSA of VAT ( Figure 2B ), lower MT attenuation ( Figure 2C ) and a tendency to have lower CSA of MT ( Figure 2D ) than controls. CSA of SCAT could be quantified in 384 subjects (327 COPD subjects and 57 controls) in whom the abdomen external wall 
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adiposity and COPD body composition parameters were particularly notable in patients with GOLD 4 COPD. Interestingly, progressively decreasing MT attenuation and CSA of MT were associated with increased probability of experiencing worse functional status and FEV 1 decline and prevalence of CVDs, while VAT accumulation was associated with the prevalence of diabetes and gastroesophageal reflux at study entry. Importantly, these associations remained after adjustment for age, sex, BMI, smoking status and FEV 1 .
We are not aware of previously published study on intra-abdominal muscle attenuation and CSA data in COPD. Similar to our findings involving the psoas, paraspinal and abdominal wall muscles, evidence of fat infiltration and atrophy of the quadriceps has been reported in COPD. 23, 24 The same authors also reported inverse relationships between indices of quadriceps' fat infiltration and walking capacity in COPD. In this context, it is interesting that lower intraabdominal MT density, a reflection of increased fatty content, and reduced muscle intra-abdominal CSAs were associated with increased probability of having a 6MWD ,350 m. It could be argued that the performance of the psoas and paraspinal muscles that are involved in walking was altered by a combination of fat infiltration and reduced area, together leading to impaired muscle contractility. 24, 25 Alternatively, intra-abdominal muscle fat infiltration and atrophy may simply be a reflection of a generalized process involving several muscle groups, including those of the lower limbs.
The mechanisms for ectopic fat accumulation in COPD were not investigated. These phenomena have been associated with insulin resistance, 26 resulting from a combination of factors, including age, genetics, poor diet, smoking and lack of vigorous physical activity, to only name a few. 10 Another potential contributor to ectopic fat accumulation in COPD that was not addressed in the present study included repeated use of systemic corticosteroid to treat COPD exacerbations. 27 We also did not have direct measurement of physical activity and dietary habits. 7 Ectopic fat is metabolically active as evidenced by its production of a host of proinflammatory mediators, including TNF-α, IL-6, leptin and adiponectin, whose effects may be seen not only locally within the AT but also at the systemic level. Considering systemic inflammation as a risk factor for CVDs and possibly for COPD progression, 28, 29 we speculated that ectopic fat accumulation would be associated with adverse clinical outcomes such as poor functional status and quality of life, increased exacerbation risk and faster FEV 1 decline as well as with cardiovascular comorbidities. Although this interpretation is partly supported by fell inside the field of view. SCAT was greater in patients with COPD than in controls ( Figure 2E ). The same results are also presented according to the severity of airflow obstruction from GOLD stages 2 to 4. Patients with GOLD 3 and 4 COPDs had lower BMI than GOLD 2 patients, while GOLD 4 patients were characterized by larger CSAs of VAT and SCAT and less MT attenuation than the remaining groups.
The associations between body composition parameters and COPD-associated clinical outcomes are shown in Figure 3 . Progressively increasing CSA of VAT was not associated with worsening in functional status (6MWD), exacerbation rate and FEV 1 decline but it was associated with a reduced odds ratio of having SGRQ scores .25 (indicating worse health status). In contrast, progressively decreasing MT attenuation and CSA of MT were associated with increased probability of exhibiting low 6MWD and accelerated FEV 1 decline. In COPD, the probability of having diabetes (P=0.024) and gastroesophageal reflux (P=0.0048) at baseline increased in parallel with VAT accumulation, while MT attenuation predicted increased probability of cardiovascular comorbidities (P=0.042; Figure 4 ). Body composition parameters did not correlate with coronary artery scores or with survival.
Discussion
This ECLIPSE substudy reports increased ectopic AT accumulation in a large group of patients with COPD compared to controls with normal lung function. Patients with COPD were characterized by increased CSA of VAT and evidence of muscle fat infiltration as assessed by CT as well as by an increased prevalence of cardiovascular comorbidities. Our study is concordant and extends existing knowledge that patients with COPD are associated with increased VAT accumulation compared to controls 7, 22 by reporting, for the first time, decreased MT attenuation (consistent with increased fat infiltration) in COPD and investigating the relationship between ectopic fat accumulation and COPDrelated outcomes and comorbidities. Alterations in CT 
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Martin et al our data, the reported association between ectopic fat accumulation, clinical outcomes and comorbidities should not be viewed as implying causal relationships. Nevertheless, these associations point to the fact that ectopic fat accumulation could be detrimental to cardiovascular and metabolic health in COPD.
Investigators from the COPDGene study reported a significant association between the amount of VAT and the risk of having a history of a previous myocardial infarction in patients with COPD. 30 In the present investigation, we found that CSA of VAT and muscle attenuation were, respectively, associated with increased prevalence of diabetes and cardiovascular 
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adiposity and COPD comorbidities at study entry. These results are consistent with the bulk of knowledge recognizing ectopic fat accumulation as a risk factor for cardiovascular and metabolic diseases. 10 We did not find, however, an association between the extent of coronary artery calcification and VAT in this cohort. This may be an indication that the mechanisms by which VAT contributes to CVD risk do not mainly involve a calcification process.
Our study has several strengths. It involves an appreciable number of patients with longitudinal follow-up, offering the possibility of studying the clinical consequences of ectopic fat accumulation. The international scope of the study also supports the generalizability of the data. Body composition analysis was performed rigorously, according to standardized and recommended procedures. 13 There are however potential limitations that need to be considered in interpreting the data. Despite the relatively large study sample and the 3-year follow-up, the number of deaths (n=50) was likely too small to secure the notion of a possible relationship between ectopic fat accumulation and survival in COPD. Because ECLIPSE CT scans were not performed purposely to determine body composition, the analysis had to be restricted to those participants with abdominal CT images, which would be valid for segmentation of AT and muscle area and densities. We do not believe, however, that these issues compromise the validity of our findings because baseline characteristics of patients involved in this substudy were similar to those of the entire ECLIPSE cohort. 12 ECLIPSE did not mandate to match control subjects with patients with COPD. As such, important differences in age, sex distribution and smoking status were seen between the two groups. This issue was addressed by controlling for baseline differences for these variables in all analyses. In addition, physical activity levels were not assessed, making it difficult to comment on the potential impact of sedentary behaviors on the body composition differences observed in COPD in this cohort. Although ECLIPSE was a considerable undertaking, it remains that 3 years of follow-up was likely too short to highlight the clinical impact of body composition abnormalities, particularly in this cohort of patients with advanced COPD. Finally, some important well-established cardiovascular risk factors such as lipid and glycemic profile were not assessed. In this regard, it could be argued that these traditional risk factors could at least partly capture the elevated cardiovascular risk in COPD.
Conclusion
Our study adds to the existing knowledge by confirming the presence of increased ectopic fat accumulation in COPD. In this patient population, body composition abnormalities in the form of increased CSA of VAT and fat infiltration of intraabdominal muscle and reduced CSA of intra-abdominal muscle were associated with cardiovascular comorbidities, diabetes and gastroesophageal reflux as well as with relevant clinical outcomes such as walking capacity and FEV 1 decline. As successfully accomplished in other patient populations, we submit that assessing the level of ectopic fat accumulation is relevant in COPD. In addition, we suggest that we should also consider the development of lifestyle modification programs focusing on both nutritional quality and physical activity/exercise with the objective of improving AT distribution/ectopic fat in patients with COPD.
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